While both WCK 5222 and WCK 4873 target bacterial infections arising from resistance to existing antibiotics, thats where there similarities end.
For starters, WCK 4873 targets gram-positive streptococcus pneumoniae while WCK 5222 targets P. aeroginosa, A. baumannii and E. coli/klebsiella which are gram-negative (harder to treat). If you see the variety of ways different bacteria can cause infections in the previous post towards the beginning, you would have noticed that some of them are airborne or spread via community, while some of them spread mainly in hospital settings. This also changes the way they get treated – community-acquired pneumonia is likely to cause respiratory issues like a common cold while hospital-acquired infections are likely to cause more serious life-threatening issues in immuno-compromised patients who are already down with cancer or organ-transplant or some other issue.
Consequently, everything from the way antibiotics are. administered (could be oral formulations for WCK 4873 vs via IV for WCK 5222) or marketed (you have to have good distribution for WCK 4873 while WCK 5222 might only need you to reach out to hospitals and so on) varies.
WCK 4873 or Nafithromycin is proven to be effective in the Chinese respiratory illness. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549737/pdf/dlac103.pdf. Wockhardt has outlicensed this to Jemincare for sale in China.
Will this target Azithromycin market? I highly doubt it. I dont think stronger antibiotics like WCK 4873 will be used before Azithromycin.
| Subscribe To Our Free Newsletter |
